N@N

Halozyme Therapeutics Inc (NASDAQ:HALO), Up By 127.67% ($5.49) From $4.300 After BUYINS.NET Report Predicted Strength After Ea

^{Published on 2012-08-07 07:43:04 - WOPRAI}
 

August 7, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, August 3rd 2012 stating that Halozyme Therapeutics Inc (NASDAQ:HALO) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=halo&id=298108

At the time this story was written, Halozyme Therapeutics Inc (NASDAQ:HALO) is Up By 127.67% ($5.49) From $4.300 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Halozyme Therapeutics Inc (NASDAQ:HALO) - Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. Its portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. The companys Enhanze technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. It has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. to apply Enhanze Technology to Roches biological therapeutic compounds for up to 13 targets; and with Baxter Healthcare Corporation to apply Enhanze Technology to Baxters biological therapeutic compound, GAMMAGARD LIQUID, as well as to develop and supply active pharmaceutical ingredient for HYLENEX, a product used as an adjuvant to increase the dispersion and absorption of other injected drugs and fluids. The company was founded in 1998 and is based in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Halozyme Therapeutics Inc (NASDAQ:HALO) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net